San Francisco startup Structure Therapeutics is also engaged on an oral, once-daily GLP-1 drug referred to as GSBR-1290—the drug surpassed Wall Road’s anticipations in June any time a mid-phase study showed ordinary weight loss of about 6% and it designs to start One more mid-stage t